Skip to main content

Table 2 The available cases of non-parathyroid hormone-dependent hypercalcemia in acromegaly

From: Acromegaly and non‐parathyroid hormone‐dependent hypercalcemia: a case report and literature review

Study ID

Age

Sex

Course

years

Time and

reference range

GH

ng/ml

IGF-1

ng/ml

PRL

ng/ml

Sca

mg/dL

Sp

mg/dL

Uca

mg/24h

PTH

Pg/mL

25D

ng/ml

1,25D

pg/ml

2010Shah1

50/F

2+

on addmission

14.5

911

33

10.3

-

388

20

34

119

3-month Post

1.4

197

11.3

10.0

-

152

41

48

50

Normal range

0.03-10

49-292

1-24

8.6-10.2

-

100-300

10-65

30-80

15-75

2010Shah2

51/F

2+

on addmission

75.8

425

67.1

10.7

-

-

19

44

66

1-week Post

18.5

246

36

8.5

-

-

-

-

-

2-month Post

12.8

440

10

10.7

-

199

23

30.6

81.3

Normal range

0.03-10

49-292

1-24

8.6-10.2

-

100-300

10-65

30-80

15-75

2014Pooja

67/F

10+

on addmission

92.0

1498

223.2

10.7

4.1

356.4

13

30.2

72.6

3-month Post

1.07

304

4.2

9.9

4.3

192.6

25

45.3

38.6

Normal range

0-3.61

59-225

2-17.4

8.5-10.5

2.5-4.9

100-300

10-60

31-80

15-60

Present report

37/M

6+

on addmission

15.5

>600

585

10.7

5.48

231.3

24

15.9

-

3-month Post

1.26

154.85

2.92

9.4

4.15

48.6

52.5

22.8

-

Normal range

0.03-2.5

86-196

4.6-21

8.5-10.1

2.6-4.6

100-300

14-63

19-58

-

  1. GH indicates growth hormone, IGF-1 insulin-like growth factor-1, PRL prolactin, Sca serum calcium, Sp serum phosphorus, Uca urinary calcium, PTH parathyroid hormone, 25D 25 hydroxyvitamin D, 1,25D 1,25-dihydroxyvitamin D, Post post-treatment, F female, M male, -, no data